LSL Pharma Group has completed the acquisition of Laboratoire Du-Var Inc. a contract manufacturer of cosmetics and natural health products established in 1947.
Through this acquisition, LSL Pharma will immediately more than double its production capacity for liquid and semi-solid products, in addition to complementing manufacturing infrastructure to its existing facilities. The integration of Du-Var will also enable the company to expand its customer base in the CMO segment, while giving it access to new markets in the natural health products, cosmetics, personal care, and pet care.
"This acquisition marks another important milestone in LSL Pharma's growth. It not only allows us to significantly increase our production capacity for liquid and semi-solid products, but also to diversify our offering and attract new customers in segments that complement our core businesses," said François Roberge, President and CEO of LSL Pharma. "Du-Var enjoys a solid reputation and its expertise has been recognized for over 75 years. We are delighted to welcome its team to LSL Pharma," he added.
This transaction is part of LSL Pharma's strategic plan, which aims to build an integrated pharmaceutical, cosmetic, and natural health products manufacturing hub in Canada, combining innovation, quality, and operational flexibility. The effective date of the transaction is November 17, 2025.